Current Report Filing (8-k)
July 02 2020 - 5:39PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
June 26, 2020
Onconova Therapeutics, Inc.
(Exact name of Registrant as specified in
its charter)
Delaware
|
|
001-36020
|
|
22-3627252
|
(State or Other Jurisdiction
of Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
375 Pheasant Run
Newtown, PA 18940
(267) 759-3680
(Address, Including Zip Code, and Telephone
Number, Including Area Code, of Registrant’s Principal Executive
Offices)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $.01 per share
|
|
ONTX
|
|
The Nasdaq Stock Market LLC
|
Common Stock Warrants
|
|
ONTXW
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
Item 5.07. Submission of Matters to a Vote of Security Holders.
Onconova Therapeutics, Inc. (the “Company”) previously
disclosed the vote results for Proposals 1, 3, 4, 5 and 6, each as set forth in the Company’s definitive proxy statement
filed with the Securities and Exchange Commission (the “SEC”) on April 23, 2020 (the Proxy Statement”) for the
Company’s 2020 Annual Meeting of Stockholders held on May 27, 2020 (the “Annual Meeting”) under Item 5.07 in
the Company’s Current Report on Form 8-K filed with the SEC on June 2, 2020.
The Company also previously disclosed that it adjourned the
Annual Meeting to June 26, 2020 (the “Reconvened Annual Meeting”) to give the Company’s stockholders additional
time to consider and vote on Proposal 2 regarding a reverse stock split as set forth in the 2020 Proxy Statement. The Company subsequently
disclosed that, based on feedback from the Company’s stockholders, the Company intended to withdraw Proposal 2 from consideration
by the Company’s stockholders at the Reconvened Annual Meeting and added Proposals 7 and 8 as matters to be voted on at the
Reconvened Annual Meeting and distributed relevant additional proxy materials to the Company’s stockholders.
On June 26, 2020, the Company held the Reconvened Annual Meeting.
At the Reconvened Annual Meeting, the Company withdrew Proposal 2 and the Company’s stockholders voted on the following proposals:
Proposal 7. To consider and vote upon Amendment 2020-1 to the
2018 Omnibus Incentive Compensation Plan, as amended and restated. The proposal was not approved by a vote of the stockholders
as follows:
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
|
12,129,142
|
|
13,499,081
|
|
3,059,252
|
|
None
|
|
Proposal 8. To consider and vote upon a proposal to adjourn
the Reconvened Annual Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at
the time of the Reconvened Annual Meeting to approve Proposal 7. The proposal was not approved by a vote of the stockholders as
follows:
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
|
12,476,244
|
|
14,092,722
|
|
2,118,509
|
|
None
|
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: July 2, 2020
|
|
Onconova Therapeutics, Inc.
|
|
|
|
|
|
By:
|
/s/ MARK GUERIN
|
|
|
|
Name:
|
Mark Guerin
|
|
|
|
Title:
|
Chief Financial Officer
|
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Apr 2023 to Apr 2024